Blurbs

Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Reata Pharmaceuticals (RETA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karuna Therapeutics (KRTXResearch Report) and Reata Pharmaceuticals (RETAResearch Report) with bullish sentiments.

Karuna Therapeutics (KRTX)

In a report released yesterday, Chris Howerton from Jefferies reiterated a Buy rating on Karuna Therapeutics, with a price target of $284.00. The company’s shares closed last Friday at $205.90.

According to TipRanks.com, Howerton is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.2% and a 36.1% success rate. Howerton covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Apellis Pharmaceuticals, and Avadel Pharmaceuticals.

Currently, the analyst consensus on Karuna Therapeutics is a Strong Buy with an average price target of $287.00, a 36.2% upside from current levels. In a report issued on October 5, Mizuho Securities also maintained a Buy rating on the stock with a $276.00 price target.

See today’s best-performing stocks on TipRanks >>

Reata Pharmaceuticals (RETA)

In a report issued on October 14, Maury Raycroft from Jefferies maintained a Buy rating on Reata Pharmaceuticals, with a price target of $70.00. The company’s shares closed last Friday at $30.21, close to its 52-week low of $18.47.

According to TipRanks.com, Raycroft is a 3-star analyst with an average return of 1.0% and a 37.3% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, KalVista Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on Reata Pharmaceuticals is a Moderate Buy with an average price target of $51.25, which is an 88.4% upside from current levels. In a report issued on October 11, Citigroup also maintained a Buy rating on the stock with a $48.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on KRTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More